The global Rare Inflammatory Disease Treatment Market is poised for consistent growth, registering a compound annual growth rate (CAGR) of 4.6% from 2022 to 2028. With a valuation of USD 12,664 million in 2021, the market is projected to reach an impressive USD 17,335.8 million by the end of the forecast period.
Key Growth Drivers
The increasing prevalence of rare inflammatory conditions, coupled with advancements in treatment modalities and government initiatives to support rare disease research, is fueling market growth. Growing awareness and the rising availability of targeted therapies also contribute to the market’s upward trajectory.
Key Takeaways
- Market Valuation in 2021: USD 12,664 million.
- Projected Valuation by 2028: USD 17,335.8 million.
- CAGR: 4.6% from 2022 to 2028.
- Drivers: Increasing prevalence of rare diseases, advancements in targeted therapies, and supportive government policies.
Regional Analysis
- North America: Dominates the market, attributed to advanced healthcare infrastructure, high R&D investments, and extensive availability of innovative treatments.
- Europe: Second-largest market, driven by increased funding for rare disease research and growing awareness of early diagnosis.
- Asia-Pacific: Expected to exhibit the fastest growth, propelled by improving healthcare systems, rising awareness, and increasing focus on rare disease management.
- Latin America & Middle East/Africa: Emerging regions with growing initiatives to address rare diseases and improve access to treatments.
Rare Inflammatory Disease Treatment Market – Competitive Landscape
Prominent treatment providers are emphasizing on advancing drug and treatment offerings by initiating a series of clinical studies as well as forging collaborative and acquisition agreements with existing pharmaceutical companies.
- In December 2021, Pfizer Inc. announced that it had reached a definitive agreement to acquire Arena Pharmaceuticals Inc., which is developing innovative possible treatments for a variety of immuno-inflammatory diseases. The proposed acquisition offers best-in-class treatment to address unmet clinical needs for more patients with immuno-inflammatory diseases
- Likewise, in November 2021, Regeneron Pharmaceuticals Inc. announced additional positive results from a Phase 3 trial run jointly with NIAID on the use of single dose of investigational REGEN-COV® 1,200 mg sub-cutaneous injections. The findings revealed that the drug successfully protects healthy individuals from contracting COVID-19 with a success rate of 81.6%
Key Companies Profiled
- Novartis AG
- Abbvie Inc.
- Abbott Laboratories
- Regeneron Pharmaceuticals Inc.
- Swedish Orphan Biovitrum AB
- Pfizer, Inc.
- Valeant Pharmaceutical International Inc. (Bausch Health)
- Mallinckrodt Plc.
- Johnson & Johnson
Grab Your Complete Report Instantly
Key Segments Covered in Rare Inflammatory Disease Treatment Industry Survey
Rare Inflammatory Disease Treatment by Indication
- RID Treatment for Ulcerative Colitis
- RID Treatment Juvenile Rheumatoid Arthritis
- RID Treatment Psoriatic Arthritis
- RID Treatment Other Indications
Rare Inflammatory Disease Treatment by Drug Class
- Biologics-based RID Treatment
- Organic Compounds-based RID Treatment
Rare Inflammatory Disease Treatment by Mode of Administration
- RID Injectables
- Oral RID Treatment
- Other RID Treatment Administration Modes
Rare Inflammatory Disease Treatment by Distribution Channel
- RID Treatment through Hospital Pharmacies
- RID Treatment through Retail Pharmacies
- RID Treatment through Online Pharmacies
Rare Inflammatory Disease Treatment Market by Region
- North America RID Treatment Market
- Latin America RID Treatment Market
- Europe RID Treatment Market
- Asia Pacific RID Treatment Market
- Middle East & Africa (MEA)
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube